Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Swiss pharmaceutical company Roche is considering divesting its cancer data specialist Flatiron Health, valued at $1.9 billion, according to a report by the Financial Times. The decision comes as Flatiron has struggled to generate profits, although its data has been beneficial in improving cancer drug development at Roche. The report cites people familiar with the matter, indicating that Roche is exploring various options for the startup.
Roche considers options for $1.9bn cancer data start-up https://t.co/oTwmBoQQ0i $ROG.SW | $RO.SW | $RHHBY 🇨🇭 Roche https://t.co/QhW68hDQ5J
Roche considering divesting $1.9 bln cancer data startup, FT reports https://t.co/rHU9wEjD5U https://t.co/UGXtxvb49k
Roche considers options for $1.9bn cancer data start-up: “Despite Flatiron struggling to make money, one benefit of the acquisition is that its data has helped to improve cancer drug development at Roche” https://t.co/zWTHgHpwYJ
